Kirk Perry has been appointed as the interim Chief Executive Officer of Kenvue. He announced the development through a ...

Kenvue reported a 4.0% year-on-year drop in net sales for Q2 2025, lowered its full-year guidance, and continues its review ...

Non-GAAP earnings per share of $0.29 in Q2 FY2025 beat expectations, but GAAP revenue missed estimates and GAAP net sales declined 4.0% from the prior year. Management lowered its FY2025 outlook, now ...

Q2 2025 Earnings Call Transcript August 7, 2025 Kenvue Inc. beats earnings expectations. Reported EPS is $0.29, expectations ...

Kenvue, facing investor pressure and lackluster performance in its skin health and beauty unit, has cut its annual sales ...

Q2 2025 Management View Kirk L. Perry, Interim CEO, addressed his first earnings call, emphasizing the urgency of leadership changes and a comprehensive strategic alternatives review, stating the ...

Kenvue forecast its annual profit below Wall Street estimates, as it undergoes a strategic review, which investors expect ...

The Summit, N.J., drugmaker said Monday that both net and organic sales are likely to be down by low single-digit percentages from last year. It previously guided for net sales to grow 1% to 3%, and ...

Kenvue Inc. shares fell 3.4% in premarket trading after the consumer health company reported second-quarter results that ...

(NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of ...

EARNINGS: The Johnson & Johnson spinoff, which makes Tylenol and Benadryl, is expected to post a profit of $482.3 million, or 25 cents a share, according to analysts surveyed by FactSet. That compares ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk Perry as interim CEO. Yahoo Finance Senior Healthcare Reporter Anjalee ...